To cite this paper use one of the standards below:
We present the case of a 64-year-old woman, with essential hypertension, referred to our hospital for investigation of refractory epilepsy. She had a history of prolonged inpatient treatment in another hospital due to several complications of her state: bronchoaspiration, pneumonia, hyponatremia of hard control. The patient had already received a loading dose of phenobarbital followed by phenytoin due to long-duration seizures.
Upon admission, the patient exhibited decreased mental status, diurnal excessive somnolence, episodes of hyponatremia and seizures characterized by fasciobrachial dystonias. While seizures were initially controlled, the patient progressed to a non-convulsive status epilepticus, necessitating a loading dose of levetiracetam for management.
Suspecting autoimmune encephalitis, we conducted thorough laboratory investigations and a lumbar puncture, initially yielding no remarkable results. Consequently, the patient received pulse therapy with methylprednisolone (1 gram daily for five days), followed by maintenance treatment with prednisone (50 milligrams daily). Subsequent improvement in the patient's condition was observed, with resolution of seizures and hyponatremia, and gradual improvement in mental status.
Analysis of the autoimmune panel of cerebrospinal fluid revealed positivity for anti-LGI1 antibodies, confirming the diagnosis of autoimmune limbic encephalitis. Autoimmune encephalitis, particularly anti-LGI1 subtype, is often underdiagnosed despite its significant clinical manifestations, including seizures, hyponatremia, and fasciobrachial dystonic seizures. Treatment primarily involves pulsed corticosteroid therapy followed by maintenance with prednisone. Our patient exhibited an excellent response to corticosteroids, allowing for gradual tapering of prednisone dosage.
This case underscores the importance of considering autoimmune encephalitis in patients presenting with refractory seizures and associated clinical features. Prompt diagnosis and initiation of appropriate treatment are essential for favorable outcomes in these patients.
With nearly 200,000 papers published, Galoá empowers scholars to share and discover cutting-edge research through our streamlined and accessible academic publishing platform.
Learn more about our products:
This proceedings is identified by a DOI , for use in citations or bibliographic references. Attention: this is not a DOI for the paper and as such cannot be used in Lattes to identify a particular work.
Check the link "How to cite" in the paper's page, to see how to properly cite the paper